

Table S1. The linkage disequilibrium between each SNP pair.

R²	rs2071346	rs10110283	rs3824120	rs3891248
rs4645948	0.663	0.000	0.010	0.023
rs2071346	--	0.002	0.013	0.027
rs10110283	--	--	0.012	0.012
rs3824120	--	--	--	0.008

Table S2. Patient treatment and clinical characteristics.

Patient characteristics	Cases (N=505)
Gender	
Male	374 (74.1)
Female	131 (25.9)
Age, years	
Mean±SD	47.41±9.15
< 47	229 (45.3)
≥ 47	276 (54.7)
BMI	
< 18.5	30 (5.9)
18.5 ~ 24	274 (54.3)
≥ 24	201 (39.8)
Smoking status	
Smoker	247 (48.9)
Nonsmoker	258 (51.1)
Drinking status	
Drinker	90 (17.8)
Nondrinker	415 (82.2)
Histological type	
WHO type II	214 (42.4)
WHO type III	291 (57.6)
Clinical stage^a	
I-II	50 (9.9)
III-IV	455 (90.1)
T-staging	
T1-T2	246 (48.7)
T3-T4	259 (51.3)
N-staging	
N0-N1	93 (18.4)

N2-N3	412 (81.6)
IC regimen	
DP	200 (39.6)
FP	92 (18.2)
TP	203 (40.2)
GP	10 (2.0)
CCRT regimen	
FP	85 (16.8)
TP	108 (21.4)
DDP	83 (16.4)
NDP	172 (34.1)
DP	57 (11.3)
pGTVnx (irradiation dose)	
Mean ± SD	71.34 ± 2.79
< 71.00Gy	261 (51.7)
≥ 71.00Gy	234 (48.3)
CCRT- induced toxic reactions^b	
Grade 3-4 Dermatitis	51 (10.1)
Grade 3-4 Oral mucositis	129 (25.5)
Grade 3-4 Myelosuppression	121 (24.0)
Grade 3-4 Neutropenia	94 (18.6)
Grade 3-4 Leukopenia	73 (14.5)
Anemia	217 (43.0)
Thrombocytopenia	98 (19.4)

Abbreviations: BMI: Body mass index; CCRT: Concurrent chemoradiotherapy; IC: Induction chemotherapy; DP: Docetaxel + Cisplatin/Nedaplatin; FP: 5-fluorouracil + Cisplatin/Nedaplatin; TP: Paclitaxel + Cisplatin/Nedaplatin; GP: Gemcitabine + Cisplatin/Nedaplatin; DDP: Cisplatin alone; NDP: Nedaplatin alone.

^a2002 American Joint Committee on Cancer (AJCC) staging system;

^bCommon Terminology Criteria for Adverse Events (CTCAE 3.0)

Table S3. Haplotype analysis of selected MYC locis and their association with the risk of nasopharyngeal carcinoma.

Haplotypes ^a	Cases (Freq)	Controls (Freq)	OR (95% CI)	P
C G A G	82.99 (0.061)	89.14 (0.055)	1.141 (0.838-1.553)	0.401
C G A T	0.11 (0.000)	0.03 (0.000)	--	--
C G G G	787.83 (0.583)	1008.67 (0.620)	0.875 (0.753-1.016)	0.080
C G G T	170.91 (0.126)	229.97 (0.141)	0.889 (0.719-1.101)	0.281
C T A G	0.09 (0.000)	4.35 (0.003)	--	--

CTAT	0.00 (0.000)	0.10 (0.000)	--	--
CTGG	67.83 (0.050)	75.13 (0.046)	1.103 (0.788-1.545)	0.567
CTGT	7.24 (0.005)	11.61 (0.007)	--	--
TGAT	0.00 (0.000)	0.92 (0.001)	--	--
TGGG	2.12 (0.002)	2.11 (0.001)	--	--
TGGT	1.04 (0.001)	1.15 (0.001)	--	--
TTAG	12.04 (0.009)	6.13 (0.004)	--	--
TTAT	2.77 (0.002)	1.33 (0.001)	--	--
TTGG	203.11 (0.150)	193.47 (0.119)	1.327 (1.074-1.641)	0.009
TTGT	13.92 (0.010)	3.88 (0.002)	--	--

^a The haplotypes order were rs4645948, rs2071346, rs10110283 and rs3824120. All those frequency < 0.03 will be ignored in analysis.




Figure S1. Linkage disequilibrium analysis for the five selected polymorphisms in the MYC gene.